Search results for "antineoplastic"

showing 10 items of 2217 documents

Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs

1996

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes alkyl groups from the O6 position of guanine in DNA and thus may protect cells against genotoxic effects of agents inducing this lesion. To analyze quantitatively the level of protection mediated by MGMT against antineoplastic drugs, we determined the cytotoxic and recombinogenic (sister-chromatid exchange inducing) effects of various chemotherapeutic agents in a pair of isogenic Chinese hamster cell lines deficient and proficient for MGMT, generated upon transfection with human MGMT cDNA. Furthermore, we compared the responses of the human cell lines HeLa MR (MGMT deficient) and HeLa S3 (MGMT proficient) to the va…

MelphalanCancer ResearchMethyltransferaseCell SurvivalAntineoplastic AgentsCHO CellsDNA methyltransferaseHeLaO(6)-Methylguanine-DNA Methyltransferasechemistry.chemical_compoundMafosfamideCricetinaemedicineAnimalsCytotoxic T cellneoplasmsCisplatinGeneticsbiologyChlorambucilMethyltransferasesbiology.organism_classificationdigestive system diseasesOncologychemistryCancer researchSister Chromatid Exchangemedicine.drugInternational Journal of Cancer
researchProduct

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct

Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells

2016

Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and res…

Mesothelioma0301 basic medicinePathologymedicine.medical_specialtyLung NeoplasmsAntineoplastic AgentsPemetrexedHMGB1DeoxycytidineArticleProinflammatory cytokineBALB/c03 medical and health sciences0302 clinical medicineImmune systemMalignant MesotheliomCell Line TumormedicineMesothelioma HMGB1 in vivo imagingcancerAnimalsHumansMesotheliomaHMGB1 ProteinCisplatinMice Inbred BALB CMultidisciplinarybiologybusiness.industryMesothelioma Malignantbiology.organism_classificationmedicine.diseaseSurvival AnalysisGemcitabine030104 developmental biologyPemetrexedCell culturemesothelioma030220 oncology & carcinogenesisbiology.proteinFemaleCisplatinBALB/cbusinessImmunocompetenceNeoplasm Transplantationmedicine.drug
researchProduct

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma

2016

A series of 22 derivatives of the [1,2]oxazolo[5,4-e]isoindole system were synthesized through an efficient and versatile procedure that involves the annelation of the [1,2]oxazole moiety to the isoindole ring, producing derivatives with a wide substitution pattern. The structure-activity relationship indicates that the N-4-methoxybenzyl group appears crucial for potent activity. In addition, the presence of a 6-phenyl moiety is important and the best activity is reached with a 3,4,5-trimethoxy substituent. The most active compound, bearing both the structural features, was able to inhibit tumor cell proliferation at nanomolar concentrations when tested against the full NCI human tumor cell…

MesotheliomaLung NeoplasmsMice NudeAntineoplastic AgentsApoptosisIsoindoles01 natural sciencesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoDrug DiscoveryTumor Cells CulturedAnimalsHumansMoietyPeritoneal NeoplasmsCell ProliferationOxazoleDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryCell growthMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCell CycleMesothelioma MalignantNeoplasms ExperimentalSettore CHIM/08 - Chimica FarmaceuticaIn vitro0104 chemical sciencesMedicine (all); Molecular Medicine; Drug Discovery3003 Pharmaceutical ScienceBiochemistryApoptosisCell culture030220 oncology & carcinogenesisMolecular MedicineDrug Screening Assays AntitumorIsoindoleJournal of Medicinal Chemistry
researchProduct

Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.

2013

In this study, we describe the synthesis of new nortopsentin analogues, 1H-pyrrolo[2,3-b]pyridine derivatives and their biological effects in experimental models of diffuse malignant peritoneal mesothelioma (DMPM), a rare and rapidly fatal disease, poorly responsive to conventional therapies. The three most active compounds, 1f (3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-b]pyridine), 3f (3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine), and 1l (3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b] pyridine), which were shown to act as cyclin-dependent kinase 1 inhibitors, consistently reduced DMPM cell prol…

MesotheliomaMagnetic Resonance SpectroscopyCell growthKinasePyridinesAntineoplastic AgentsPharmacologyCell Linechemistry.chemical_compoundchemistryPaclitaxelApoptosisCell cultureDrug DiscoveryPyridineSurvivinMolecular MedicineCytotoxic T cellHumansSpectrophotometry UltravioletPeritoneal NeoplasmsJournal of medicinal chemistry
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

Metal drugs and the anticancer immune response

2018

The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting…

Metal Drugs Immune Response Anticancer cisplatinanimal diseasesmedicine.medical_treatmentEvasion (network security)chemical and pharmacologic phenomenaAntineoplastic Agents010402 general chemistry01 natural sciencesMalignant transformationImmune systemImmunityCoordination ComplexesNeoplasmsmedicineHumansLymphocytesTumor microenvironment010405 organic chemistryChemistryGeneral ChemistryImmunotherapybiochemical phenomena metabolism and nutritionAcquired immune systemImmunity Innate0104 chemical sciencesGastrointestinal MicrobiomeMetalsSettore CHIM/03 - Chimica Generale E InorganicaCancer cellbacteriaNanoparticlesImmunotherapyNeuroscience
researchProduct

3,5-bis(3'-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: synthesis and antitumor properties.

2007

A series of 10 bis-indolylpyrazoles of type 9, 10 were obtained by cyclization of diketones 8 using hydrazine monohydrate or methylhydrazine in refluxing acetic acid/THF. Derivatives 9a,c,d were selected, by the National Cancer Institute (NCI, Bethesda, USA), to be evaluated against the full panel of about 60 human tumor cell lines derived from nine human cancer cell types and showed antiproliferative activity in the micromolar range. In particular, 9d, the most active compound was effective against all the tested cell lines with a GI(50) mean value of 3.23 microM; TGI and LC(50) values were 14.5 and 58.9 microM having positive response on 91% and 41% of the tested cell lines, respectively.

MethylhydrazineIndolesStereochemistry3Clinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsBiochemistryChemical synthesisNortopsentin; 3; 5-Bis(3'-indolyl)pyrazoles; antitumor activity; Topoisomerase IIAcetic acidchemistry.chemical_compoundAlkaloidsCell Line TumorDrug DiscoveryHumansantitumor activityMolecular BiologyCell Proliferationchemistry.chemical_classificationCell growthAlkaloidNortopsentinOrganic ChemistryImidazolesBiological activity5-Bis(3'-indolyl)pyrazolesTopoisomerase IIEnzymechemistryCell cultureMolecular MedicinePyrazolesDrug Screening Assays AntitumorBioorganicmedicinal chemistry letters
researchProduct

Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide

2006

DNA double-strand breaks (DSBs) are potent killing lesions, and inefficient repair of DSBs does not only lead to cell death but also to genomic instability and tumorigenesis. DSBs are repaired by non-homologous end-joining and homologous recombination (HR). A key player in HR is Xrcc2, a Rad51-like protein. Cells deficient in Xrcc2 are hypersensitive to X-rays and mitomycin C and display increased chromosomal aberration frequencies. In order to elucidate the role of Xrcc2 in resistance to anticancer drugs, we compared Xrcc2 knockout (Xrcc2-/-) mouse embryonic fibroblasts with the corresponding isogenic wild-type and Xrcc2 complemented knockout cells. We show that Xrcc2-/- cells are hypersen…

MethylnitronitrosoguanidineCancer ResearchProgrammed cell deathDNA repairDNA damageMitomycinApoptosisBiologyNitrosourea Compoundschemistry.chemical_compoundOrganophosphorus CompoundsMafosfamideTemozolomidemedicineHumansCytotoxic T cellAntineoplastic Agents AlkylatingCyclophosphamideCisplatinMolecular biologyDNA-Binding ProteinsDacarbazineOncologychemistryApoptosisFotemustineCisplatinMutagensmedicine.drugCancer Letters
researchProduct

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

2006

Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. Transfection experiments with O(6)-methylguanine-DNA methyltransferase (MGMT) and depletion of MGMT by O(6)-benzylguanine showed that, in gliomas, the apoptotic signal originates from O(6)-methylguanine (O(6)MeG) and that repair of O(6)MeG by MGMT prevent…

MethylnitronitrosoguanidineCancer ResearchProgrammed cell deathFas Ligand ProteinGuanineDNA repairFas-Associated Death Domain ProteinBlotting WesternApoptosisBiologymedicine.disease_causeO(6)-Methylguanine-DNA MethyltransferaseGliomaTemozolomideTumor Cells CulturedGeneticsmedicineHumansDNA Breaks Double-StrandedRNA Small InterferingAntineoplastic Agents AlkylatingneoplasmsMolecular BiologyTumor Stem Cell AssayCell ProliferationTemozolomideBrain NeoplasmsCell CycleGliomaCell cycleFlow CytometryFas receptormedicine.diseaseDacarbazineProto-Oncogene Proteins c-bcl-2ApoptosisCaspasesCancer researchTumor Suppressor Protein p53CarcinogenesisDNA Damagemedicine.drugOncogene
researchProduct